AR and bone metastasis: Prior to starting Ra-223 therapy, 58 patients had undergone external radiotherapy for bone metastasis, 158 received novel androgen receptor-targeted agent therapy with enzalutamide and/or abiraterone, 91 received taxane-based chemotherapy with docetaxel and/or cabazitaxel, and 144 received bisphosphonate/denosumab treatment.